openinnovation.astrazeneca.comの競合サイトトップ10

sygnaturediscovery.com

Integrated drug discovery with Sygnature’s multidisciplinary teams. From target to candidate, delivering speed and decision-ready data.

qmarkets.net

Gain the knowledge and insight needed to take your innovation management program to the next level by watching our webinars, both live and on demand.

ppd.com

Tap into insights on how to embrace a patient diversity mindset from Rodrigo Garcia, Vice President, Sites and Patients Center of Excellence, PPD clinical research business of Thermo Fisher Scientific.

dctd.cancer.gov

The Stepping Stones Program provides critical resources to advance innovative anti-cancer therapeutics toward clinical development. This initiative intends to augment grant-supported programs with access to NCI/DCTD/DTP drug development capabilities to fill knowledge and data gaps, enabling these programs to advance and procure additional resources for development toward clinical testing.

genengnews.com

In this GENcast, we chatted with two team members and picked their brains about some of the challenges currently facing manufacturers in this space. Listen in and hear what they have to say…

guidetopharmacology.org

the iuphar/bps guide to pharmacology. an expert-driven guide to pharmacological targets with quantitative information on the prescription medicines and experimental drugs that act on them. developed as a joint initiative of the international union of basic and clinical pharmacology (iuphar) and the british pharmacological society (bps) and is now the new home of the iuphar database (iuphar-db).

caymanchem.com

we manufacture high quality biochemicals, assay kits, antibodies, and recombinant proteins and offer contract services for custom chemical synthesis/analysis, assay development/screening, and drug discovery.

medchemexpress.com

MedChemExpress (MCE) provides 50,000+ selective Inhibitors and Recombinant Proteins with high purity and quality. Cited in 30,000+ publications by worldwide scientists.

selleckchem.com

Resiquimod (R-848, S28463) is an immune response modifier that acts as a potent TLR 7/TLR 8 agonist, inducing the upregulation of cytokines such as TNF-α, IL-6 and IFN-α. This compound reduces hepatitis C virus (HCV) infection. Phase 2.